Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi And Hengrui To Go To Court Again

This article was originally published in PharmAsia News

Executive Summary

In response to the verdict of non-patent infringement of Hengrui's use of docetaxel in China, Sanofi-Aventis is likely to appeal to the Beijing Number One Intermediate People's Court to further fight for its patent rights. The Greater China office says that it cannot comment on the case now but states that Sanofi holds the patent for docetaxel worldwide and its team of lawyers is preparing the necessary legal documents. Industry observers believe Sanofi is not likely to give up its fight for the patent as Taxotere, its key antitumor product using docetaxel, fetches a lucrative profit. (Click here for more - Chinese Language)
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC068496

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel